Phuturdex › Diseases › Anxiety disorder
Drugs in development · updated 30 October 2026
Anxiety disorder: drugs in development
As of 30 October 2026 there are 52 active clinical trials (recruiting or ongoing, phases I–III) on 32 drugs for anxiety disorder. 15 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| SEP-363856 | III | 3 | NCT07759128 |
| Fasedienol Nasal Spray | III | 2 | NCT06615557 |
| MelatoninSlenyto®, Circadin® | II–III | 2 | NCT05474846 |
| Ozone | II–III | 2 | NCT06799351 |
| Creatine Monohydrate | III | 1 | NCT02568878 |
| PsilocybinPsilocybine | I–II | 7 | NCT04754061 |
| Pregnenolone | II | 2 | NCT06188923 |
| SPT-300 | II | 2 | NCT07161700 |
| AFA-281 | II | 1 | NCT06710431 |
| CYB003 | II | 1 | NCT06820723 |
| Lysergic Acid Diethylamide Tartrate | II | 1 | NCT05883540 |
| RE104 for Injection | II | 1 | NCT07002034 |
| TributyrinGlycerol Tributyrate | I–II | 1 | NCT06792500 |
| Vitamin B6 | II | 1 | NCT05837104 |
| Duavive | I | 1 | NCT04478305 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CannabidiolEpidiolex, Epidyolex® | III | 5 | NCT07123467 |
| MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride® | III | 4 | NCT05681572 |
| FluoxetineSarafem®, Prozac Weekly® | III | 3 | NCT04760275 |
| KetamineKetalar® | III | 3 | NCT06835504 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT07413055 |
| DexmedetomidineIgalmi®, Precedex® | III | 1 | NCT05681572 |
| MethylphenidateConcerta, Relexxii® | II–III | 1 | NCT05474846 |
| MorphineArymo Er®, Morphabond Er® | III | 1 | NCT06835504 |
| D-CycloserineCycloserine | II | 2 | NCT07868627 |
| BuspironeBuspar® | II | 1 | NCT05511909 |
| Hydroxyzine HydrochlorideVistaril®, Atarax® | II | 1 | NCT07031206 |
| LofexidineLucemyra® | II | 1 | NCT05511909 |
| PramipexoleMirapex Er®, Sifrol® | II | 1 | NCT06269146 |
| SertralineZoloft® | II | 1 | NCT06081348 |
| Oxytocin nasal sprayOxytocin 10 Usp Units In Dextrose 5%®, Oxytocin 5 Usp Units In Dextrose 5%® | I | 1 | NCT04789148 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 32 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Obsessive-compulsive disorder 17 drugs
- Generalized anxiety disorder 12 drugs
- Trichotillomania 4 drugs
- Phobia, Social 3 drugs
- Schizophrenia 76 drugs
- Psychotic disorder 23 drugs
- Mental disorder 24 drugs
Broader categories
- Mental disorder 24 drugs
- Neurologic Manifestations 15 drugs
- Nervous System Diseases 39 drugs
- Central nervous system disease 38 drugs
- Brain Diseases 23 drugs
- Nutritional and metabolic diseases 5 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001008 “Anxiety Disorders”.